SEC 13F Intelligence

Baker Bros. Advisors LP / ACAD

Baker Bros. Advisors LP’s Acadia Pharmaceuticals Inc Position

Does Baker Bros. Advisors LP own Acadia Pharmaceuticals Inc (ACAD)? Yes — 42.90M shares worth $955M (+5.48% of its 13F portfolio) as of Q1 2026.

Position Value
$955M
Q1 2026
Shares
42.90M
% of Portfolio
+5.48%
Quarters Held
30
currently held

Position History ACAD

Reported value by quarter
Q4 ’18: $642MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.1BQ3 ’19: $1.5BQ4 ’19: $1.7BQ4 ’19Q1 ’20: $1.8BQ2 ’20: $2.0BQ3 ’20: $1.7BQ4 ’20: $2.2BQ4 ’20Q1 ’21: $1.1BQ2 ’21: $1.0BQ3 ’21: $696MQ4 ’21: $978MQ4 ’21Q1 ’22: $1.0BQ2 ’22: $591MQ3 ’22: $686MQ4 ’22: $667MQ4 ’22Q1 ’23: $789MQ2 ’23: $1.0BQ3 ’23: $893MQ4 ’23: $1.3BQ4 ’23Q1 ’24: $793MQ2 ’24: $697MQ3 ’24: $659MQ4 ’24: $787MQ4 ’24Q1 ’25: $712MQ2 ’25: $925MQ3 ’25: $915MQ4 ’25: $1.1BQ4 ’25Q1 ’26: $955Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202642.90M$955M+5.48%
Q4 202542.90M$1.1B+6.71%
Q3 202542.90M$915M+6.61%
Q2 202542.90M$925M+8.98%
Q1 202542.88M$712M+7.88%
Q4 202442.88M$787M+8.40%
Q3 202442.88M$659M+6.83%
Q2 202442.88M$697M+8.90%
Q1 202442.86M$793M+9.94%
Q4 202342.86M$1.3B+15.27%
Q3 202342.86M$893M+5.15%
Q2 202342.86M$1.0B+5.94%
Q1 202341.94M$789M+4.29%
Q4 202241.92M$667M+4.01%
Q3 202241.92M$686M+4.49%
Q2 202241.92M$591M+3.35%
Q1 202241.91M$1.0B+5.83%
Q4 202141.91M$978M+4.76%
Q3 202141.91M$696M+3.06%
Q2 202141.91M$1.0B+4.49%
Q1 202141.91M$1.1B+4.69%
Q4 202041.90M$2.2B+8.44%
Q3 202041.90M$1.7B+6.91%
Q2 202041.90M$2.0B+8.96%
Q1 202041.90M$1.8B+10.90%
Q4 201940.85M$1.7B+9.29%
Q3 201940.85M$1.5B+10.00%
Q2 201939.29M$1.1B+7.14%
Q1 201939.71M$1.1B+6.83%
Q4 201839.71M$642M+5.26%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Baker Bros. Advisors LP’s full portfolio or all institutional holders of ACAD.